Fenylefrin Unimedic

What Is Fenylefrin Unimedic and What Is It Used For?

Fenylefrin Unimedic is an injectable vasopressor containing phenylephrine hydrochloride that is used to treat low blood pressure (hypotension) during general, spinal, or epidural anaesthesia. It belongs to the group of adrenergic agents and works by selectively stimulating alpha-1 adrenergic receptors on blood vessel walls, causing vasoconstriction and raising blood pressure.

Phenylephrine is classified as a selective alpha-1 adrenergic receptor agonist, meaning it primarily acts on a specific type of receptor found on the smooth muscle cells lining blood vessels. When these receptors are activated, the smooth muscle contracts, narrowing the blood vessels and increasing systemic vascular resistance (SVR). This vasoconstriction results in a rapid and predictable increase in arterial blood pressure, making phenylephrine an essential tool in perioperative haemodynamic management.

During surgical procedures, anaesthetic agents commonly cause blood vessels to relax and dilate, which can lead to a significant drop in blood pressure. Regional anaesthesia techniques such as spinal and epidural blocks are particularly likely to cause hypotension because they block the sympathetic nerves that normally maintain vascular tone. Left untreated, perioperative hypotension can compromise blood flow to vital organs including the brain, heart, and kidneys, potentially leading to serious complications. Phenylephrine is one of the most widely used vasopressors in this clinical setting, valued for its rapid onset (1–2 minutes after intravenous administration) and its short duration of action (approximately 15–20 minutes).

Unlike many other sympathomimetic drugs, phenylephrine has minimal beta-adrenergic activity at therapeutic doses. This means it does not directly stimulate the heart to beat faster or more forcefully. In fact, the increase in blood pressure caused by phenylephrine often triggers a reflex slowing of the heart rate (reflex bradycardia) via the baroreceptor reflex. This pharmacological profile makes phenylephrine particularly useful in clinical situations where an increase in blood pressure is needed without the cardiac stimulatory effects associated with drugs like ephedrine or noradrenaline.

Phenylephrine is particularly important during caesarean section delivery under spinal anaesthesia, where maternal hypotension occurs frequently and can reduce placental blood flow. International guidelines from the European Society of Anaesthesiology (ESA) and the Society for Obstetric Anesthesia and Perinatology (SOAP) recommend phenylephrine as a first-line vasopressor for treating spinal anaesthesia–induced hypotension during caesarean sections, owing to its favourable foetal acid-base profile compared with ephedrine.

What Should You Know Before Receiving Fenylefrin Unimedic?

Before receiving phenylephrine, your anaesthesiologist will review your complete medical history, current medications, and any allergies. Phenylephrine is contraindicated in patients with hypertension, peripheral vascular disease, severe hyperthyroidism, and those taking non-selective MAO inhibitors. Special caution is required in patients with cardiovascular disease, diabetes, or glaucoma.

Contraindications

You should not receive Fenylefrin Unimedic if any of the following apply to you:

• Allergy to phenylephrine or any of the other ingredients in this medicine (sodium chloride, sodium citrate, citric acid, water for injections, hydrochloric acid, sodium hydroxide)
• Hypertension (high blood pressure) – phenylephrine would further elevate blood pressure to potentially dangerous levels
• Peripheral vascular disease – conditions involving poor blood circulation in the extremities, as vasoconstriction could worsen tissue perfusion
• Treatment with non-selective MAO inhibitors (such as iproniazid or nialamide for depression), or within 2 weeks of stopping such treatment – the combination can cause a life-threatening hypertensive crisis
• Severe thyrotoxicosis (severe overactive thyroid) – the cardiovascular system is already under significant stress and additional vasoconstriction may precipitate a cardiac event

Warnings and Precautions

Tell your doctor, pharmacist, or anaesthesiologist before receiving Fenylefrin Unimedic if you have or have had any of the following conditions. Your medical team will carefully weigh the benefits and risks and may adjust your treatment accordingly:

• Elderly age – elderly patients may be more sensitive to the blood pressure-raising effects of phenylephrine and may require lower doses
• Overactive thyroid (hyperthyroidism) – the cardiovascular effects may be exaggerated
• Heart problems including slow heart rate (bradycardia), partial heart block, cardiomyopathy, poor coronary circulation, irregular heartbeat (arrhythmia), rapid heartbeat (tachycardia), or angina – phenylephrine can affect heart function and rhythm
• Poor blood circulation in the brain (cerebrovascular insufficiency) – vasoconstriction may reduce cerebral perfusion
• Atherosclerosis (hardening and thickening of blood vessel walls) – pre-existing vascular disease may increase the risk of ischaemic complications
• Diabetes mellitus – phenylephrine may affect blood glucose levels and peripheral blood flow
• Arterial hypertension – even mild pre-existing hypertension warrants careful dose titration
• Narrow-angle glaucoma – pupil dilation caused by phenylephrine could precipitate an acute glaucoma attack
• Impaired blood circulation in the legs – vasoconstriction may worsen peripheral ischaemia

Patients with severe heart failure may deteriorate when treated with phenylephrine because the drug increases systemic vascular resistance (afterload), forcing the weakened heart to pump against greater resistance. Your anaesthesiologist will closely monitor your blood pressure and organ function throughout treatment.

Use in Children and Adolescents

Fenylefrin Unimedic is not recommended for use in children due to insufficient data on efficacy, safety, and appropriate dosing in the paediatric population. When a vasopressor is required during paediatric anaesthesia, the treating physician will select an appropriate agent and dose based on the child's age, weight, and clinical condition, using established paediatric protocols.

Pregnancy and Breastfeeding

Fenylefrin Unimedic should not be used during pregnancy unless absolutely necessary and the potential benefit to the mother justifies the potential risk to the foetus. However, it is important to note that phenylephrine is widely used during caesarean section under spinal anaesthesia, where it is considered the first-line vasopressor for treating maternal hypotension. In this specific clinical context, phenylephrine has been extensively studied and is preferred over ephedrine because it produces less foetal acidosis, as demonstrated in multiple randomised controlled trials and systematic reviews.

Regarding breastfeeding, Fenylefrin Unimedic should not be used during the breastfeeding period unless absolutely necessary. However, if you receive a single dose during delivery (for example, during a caesarean section), breastfeeding can be continued without concern. The short half-life of intravenous phenylephrine means that the drug is rapidly cleared from the body, and negligible amounts would be expected in breast milk following a single perioperative dose.

Driving and Operating Machinery

This is not relevant for Fenylefrin Unimedic, as the medication is administered in a hospital setting during surgical procedures. Patients will be under the care of their medical team before, during, and after administration. Any restrictions on driving after surgery relate to the anaesthesia and surgical procedure itself, not specifically to phenylephrine.

Sodium Content

Each 10 ml ampoule of Fenylefrin Unimedic contains 1.6 mmol (36.8 mg) sodium, equivalent to approximately 1.8% of the WHO recommended maximum daily intake of sodium for adults. Each 5 ml ampoule contains 0.8 mmol (18.4 mg) sodium, which is less than 1 mmol (23 mg), making it essentially “sodium-free”. This information is relevant for patients on a sodium-restricted diet, although in the acute perioperative setting, sodium content is rarely a limiting factor.

How Does Fenylefrin Unimedic Interact with Other Drugs?

Phenylephrine has clinically significant interactions with several drug classes, including MAO inhibitors (absolute contraindication), volatile anaesthetic agents, ergot alkaloids, tricyclic antidepressants, oxytocin, and cardiac glycosides. Always inform your anaesthesiologist about all medications you are currently taking or have recently taken.

Because Fenylefrin Unimedic is administered in a controlled hospital environment, drug interactions are managed by the anaesthesia team. However, it is essential that you provide a complete medication history before any surgical procedure so that your medical team can anticipate and prevent adverse interactions. The following tables summarise the most clinically important drug interactions with phenylephrine.

Contraindicated Combinations

Significant Interactions Requiring Caution

The list above is not exhaustive. Your anaesthesiologist has access to comprehensive drug interaction databases and will review all your current medications before administering phenylephrine. If you are taking any prescription medications, over-the-counter products, vitamins, or herbal supplements, ensure that your medical team is fully informed.

What Is the Correct Dosage of Fenylefrin Unimedic?

Fenylefrin Unimedic is administered intravenously by trained healthcare professionals. The dose is individualised based on the patient's blood pressure response and clinical condition. It is given as either bolus injections or a continuous infusion, with careful titration to achieve the desired blood pressure target.

Fenylefrin Unimedic is a hospital-only medication that is always administered by healthcare professionals with appropriate training and experience in anaesthesiology and haemodynamic management. You will not need to calculate or administer your own dose. Your anaesthesiologist will determine the correct dose, timing, and method of administration based on your individual clinical needs.

Adults

The specific dose used will depend on several factors, including the type and depth of anaesthesia, the patient's baseline blood pressure, cardiac function, volume status, and the response to initial doses. Phenylephrine is almost always used as part of a comprehensive haemodynamic management strategy that may also include intravenous fluid administration, patient positioning, and adjustment of the anaesthetic agents.

Patients with Kidney Impairment

Patients with impaired kidney function may require lower doses of phenylephrine. The kidneys play a role in the excretion of phenylephrine metabolites, and reduced renal clearance may lead to prolonged or enhanced effects. Your anaesthesiologist will take your kidney function into account when determining the appropriate dose.

Patients with Liver Impairment

Patients with impaired liver function may paradoxically require higher doses of phenylephrine. The liver is the primary site of phenylephrine metabolism via monoamine oxidase (MAO), and reduced hepatic function may alter the drug's pharmacokinetics. However, the response is variable, and careful titration based on blood pressure monitoring remains the standard approach.

Elderly Patients

Elderly patients should be treated with particular caution. Older adults often have reduced cardiovascular reserve, stiffer blood vessels (reduced arterial compliance), and may be taking multiple medications that can interact with phenylephrine. The anaesthesiologist will typically start with lower doses and titrate carefully, with close attention to blood pressure, heart rate, and overall haemodynamic status.

Children

Fenylefrin Unimedic is not recommended for children due to insufficient data on efficacy, safety, and appropriate dosing recommendations in the paediatric population. When vasopressor support is needed during paediatric anaesthesia, alternative agents with better-established paediatric dosing guidelines are typically used.

Overdose

What Are the Side Effects of Fenylefrin Unimedic?

Like all medicines, phenylephrine can cause side effects, although not everybody experiences them. The most clinically significant side effects include high blood pressure, slow heart rate (reflex bradycardia), and cardiac arrhythmias. Because the medication is given in a monitored hospital setting, side effects are promptly detected and managed by the medical team.

The side effects listed below have been reported with intravenous phenylephrine. Because this medication is used in the complex clinical environment of anaesthesia and surgery, it can sometimes be difficult to distinguish side effects of phenylephrine from effects of other anaesthetic agents, the surgical procedure itself, or the patient's underlying medical conditions. All frequencies listed below are classified as “not known” (cannot be estimated from the available data) unless otherwise specified.

Because Fenylefrin Unimedic is administered under close medical supervision, your healthcare team will be monitoring your vital signs continuously and can respond immediately to any adverse effects. If you notice any unusual symptoms after receiving this medication, inform your nurse or doctor without delay.

How Should Fenylefrin Unimedic Be Stored?

Fenylefrin Unimedic should be stored in its original packaging to protect from light. Keep out of the reach and sight of children. Do not use after the expiry date printed on the packaging.

As a hospital-only medication, Fenylefrin Unimedic is stored by the pharmacy and nursing staff under appropriate conditions. Patients do not typically need to store this medication themselves. However, the following storage information is provided for completeness and for healthcare professionals:

• Store in the original packaging – the glass ampoules must be kept in their carton to protect from light, as phenylephrine is light-sensitive
• Keep out of the reach and sight of children
• Check the expiry date (marked “EXP” on the carton) before use – the expiry date refers to the last day of the stated month
• Single use only – any unused solution remaining in an ampoule after opening should be discarded
• Do not use if the solution is not clear and colourless, or if the ampoule is damaged

Unused or expired medicines should not be disposed of via household waste or poured down drains. In a hospital setting, pharmaceutical waste is handled according to institutional protocols to protect the environment.

What Does Fenylefrin Unimedic Contain?

Each ampoule contains phenylephrine (as phenylephrine hydrochloride) as the active substance, along with sodium chloride, sodium citrate, citric acid, water for injections, and pH-adjusting agents. The solution is clear and colourless, supplied in glass ampoules.

Active Ingredient

The active substance is phenylephrine in the form of phenylephrine hydrochloride:

• Fenylefrin Unimedic 0.05 mg/ml: Each millilitre contains 0.05 mg phenylephrine (as phenylephrine hydrochloride). Each 10 ml ampoule contains a total of 0.5 mg phenylephrine.
• Fenylefrin Unimedic 0.1 mg/ml: Each millilitre contains 0.1 mg phenylephrine (as phenylephrine hydrochloride). Available in 5 ml ampoules (0.5 mg total) and 10 ml ampoules (1.0 mg total).

Inactive Ingredients (Excipients)

The other ingredients are: sodium chloride (for isotonicity), sodium citrate (buffer), citric acid (buffer), water for injections (solvent), and hydrochloric acid and sodium hydroxide (for pH adjustment). These are standard pharmaceutical excipients used to ensure the solution is safe, sterile, and compatible with intravenous administration.

Appearance and Packaging

Fenylefrin Unimedic is a clear, colourless solution for injection supplied in glass ampoules. The ampoules are packaged in plastic trays within cardboard cartons containing 5, 10, 20, 50, or 100 ampoules. Not all pack sizes may be available in your country.

Manufacturer

Fenylefrin Unimedic is manufactured by Unimedic AB and marketed by Unimedic Pharma AB. It is a product designed specifically for the hospital and clinical setting, reflecting the specialised nature of intravenous vasopressor therapy.

How Does Phenylephrine Work in the Body?

Phenylephrine is a selective alpha-1 adrenergic receptor agonist that causes constriction of peripheral blood vessels, increasing systemic vascular resistance and thereby raising arterial blood pressure. It has minimal direct cardiac stimulatory effects and typically causes reflex bradycardia. The onset of action is 1–2 minutes with intravenous bolus, and the duration of effect is approximately 15–20 minutes.

The autonomic nervous system regulates blood vessel tone through adrenergic receptors located on the smooth muscle cells of blood vessel walls. There are several subtypes of these receptors, each mediating different physiological effects. Alpha-1 adrenergic receptors are primarily responsible for vasoconstriction – the narrowing of blood vessels. When these receptors are activated, the smooth muscle cells contract, reducing the diameter of the blood vessel and increasing the resistance to blood flow.

Phenylephrine is a synthetic sympathomimetic amine that selectively binds to and activates alpha-1 adrenergic receptors. This selectivity is a key pharmacological feature that distinguishes it from other vasopressors. Unlike noradrenaline (norepinephrine), which activates both alpha and beta adrenergic receptors, phenylephrine has very little beta-1 or beta-2 adrenergic activity at clinical doses. This means that phenylephrine does not directly increase heart rate (chronotropy) or cardiac contractility (inotropy).

When phenylephrine constricts peripheral blood vessels and raises blood pressure, the baroreceptor reflex – a natural feedback mechanism – detects the increase in arterial pressure and signals the heart to slow down. This is known as reflex bradycardia and is a characteristic and expected response to phenylephrine administration. In clinical practice, this reflex slowing of the heart rate is generally well tolerated, but the anaesthesiologist monitors it closely to ensure adequate cardiac output is maintained.

Pharmacokinetic Profile

When administered as an intravenous bolus, phenylephrine has a rapid onset of action within 1–2 minutes. The blood pressure-raising effect peaks quickly and then subsides over approximately 15–20 minutes as the drug is metabolised and redistributed. This short duration of action is clinically advantageous because it allows the anaesthesiologist to make frequent, fine-grained adjustments to the patient's blood pressure.

Phenylephrine is primarily metabolised in the liver and gastrointestinal tract by the enzyme monoamine oxidase (MAO). It also undergoes conjugation reactions (sulphation and glucuronidation). The metabolites are pharmacologically inactive and are excreted predominantly by the kidneys. The relatively rapid hepatic metabolism explains why phenylephrine has such a short duration of action when given intravenously, and why patients with liver impairment may exhibit altered pharmacokinetic behaviour.

The drug's pharmacological profile – selective alpha-1 agonism, rapid onset, short duration, and predictable dose-response relationship – makes phenylephrine one of the most versatile and widely used vasopressors in modern anaesthetic practice. It is particularly valued in obstetric anaesthesia, where its favourable foetal safety profile provides an additional advantage over alternative vasopressors.

Frequently Asked Questions About Fenylefrin Unimedic